Arzanya
Arzanya operates a deep-tech platform for discovering and characterizing macrocyclic peptide ligands, which are synthetic molecules that can bind to disease-relevant therapeutic targets with high specificity. The company screens billions of macrocyclic peptide topologies using a fully trackable, adaptable approach to deliver tailored drug discovery solutions for industrial and academic partners. Its platform integrates protein production, high-throughput selection, and biophysical characterization to accelerate the development of next-generation therapeutics.
- Artificial Intelligence
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
- Software Only
Funding
Founders
Product
Problem
Traditional drug discovery approaches often struggle to generate potent and selective ligands for challenging therapeutic targets, particularly those involving protein-protein interactions or extracellular enzymes. Existing screening methods can be slow, costly, and limited in the diversity of chemical space they explore, hindering the development of treatments for complex and currently untreatable diseases.
Solution
Arzanya provides a combinatorial technology platform for the generation, quantitative screening, and fine characterization of tailored macrocyclic peptide ligands. The platform leverages a fully trackable and adaptable approach to rapidly screen billions of diverse macrocyclic peptide topologies, enabling the identification of potent and selective candidates for a wide range of therapeutic applications. Arzanya integrates protein target production, cell-based assays, and complementary biophysical techniques to deliver comprehensive molecular and biochemical characterization of lead compounds. This end-to-end pipeline offers industrial partners and research institutions a cutting-edge drug discovery solution that accelerates the path from target validation to therapeutic candidate.
Target Audience
Primary customers are pharmaceutical and biotechnology companies, as well as academic research institutions, seeking a cutting-edge drug discovery pipeline for developing macrocyclic peptide-based therapeutics against challenging disease targets.
Features
- Fully trackable combinatorial platform capable of screening billions of macrocyclic peptide topologies
- Integrated protein target production, purification, and characterization across various cell host systems
- High-throughput selection platforms for identifying and engineering macrocyclic peptide ligands with enhanced pharmacological properties
- Comprehensive molecular and biochemical characterization using complementary biophysical techniques
- Cell-based assay management for functional validation of candidate ligands
- Feasibility assessments and project design tailored to specific therapeutic targets